Clinical Trial Detail

NCT ID NCT02684058
Title Phase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

malignant glioma

Therapies

Dabrafenib + Trametinib

Age Groups: child

No variant requirements are available.